Newer drug therapy for congestive heart failure

Archives of Internal Medicine

Volumn 159, Issue 11, 1999, Pages 1177-1183

  Coodley, Eugene ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; AMIODARONE; AMLODIPINE; AMRINONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FLOSEQUINAN; FUROSEMIDE; INOTROPIC AGENT; LABETALOL; MAGNESIUM; METOLAZONE; MILRINONE; NORADRENALIN; PIMOBENDAN; PIPERANOMETOZINE; SPIRONOLACTONE; TIMOLOL; UNCLASSIFIED DRUG; XAMOTEROL; XOFENOPRIL;

BRADYCARDIA; CONGESTIVE HEART FAILURE; DRUG SCREENING; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; LUNG DISEASE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ALGORITHMS; AMIODARONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOTONIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HEART FAILURE, CONGESTIVE; HUMANS; INDANS; MAGNESIUM COMPOUNDS; NATRIURETIC PEPTIDE, BRAIN; PROPIONATES; RECEPTORS, ANGIOTENSIN;

EID: 0033553847     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.11.1177     Document Type: Review

References (54)

1. Cohen JN. Management of chronic heart failure. N Engl J Med. 1996;335:490-498.
2. Ryan TJ, Anderson JL, Antman EM, et al. ACC/ AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328-1428.
3. Clark AL, Poole-Wilson PA, Coats AJ. Exercise limitation in congestive heart failure. J Am Coll Carttiol. 1996;28:1092-1102.
4. Packer M, Carver JR, Rodeheffer RJ, et al for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468-1475.
5. Flosequinan for chronic heart failure? Drug Ther Bull. 1993;31:47-48.
6. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990; 336:1-6.
7. Cohn JN, Archibald DG, Ziesche S, et al. Effects of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med. 1986;314: 1547-1552.
8. Kass DA, Van Anden E, White WB, et al. Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy. Am J Cardiol. 1996;78:652-656.
9. Marius-Nunez AL, Heaney L, Fernandez RN, et al. Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure. Am Heart J. 1996;132:805-808.
10. Applefeld MM, Newman KA, Sutton FJ, et al. Outpatient dobutamine and dopamine infusions in the management of chronic heart failure: clinical experience in 21 patients. Am Heart J. 1987;114: 589-595.
11. Mori M, Takeuchi M, Takaoka H, et al. Oxygen-saving effect of a new cardiotonic agent, MCI-154, in diseased human hearts. J Am Coll Cardiol. 1997;29:613-622.
12. Packer M, O'Connor CM, Ghali JK, et al. Effects of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996; 335:1107-1114.
13. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
14. Gavras H, Gavras I. Cardioprotective potential of angiotensin converting enzyme inhibitors. J Hypertens. 1991;9:385-392.
15. Borghi C, Ambrosioni E, Magnani B. Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. Am J Cardiol. 1996;78:317-322.
16. Khaper N, Singal PK. Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats. J Am Coll Cardiol. 1997;29:856-861.
17. Viskin S, Barron HV. Beta blockers prevent cardiac death following a myocardial infarction: so why are so many infarct survivors discharged without beta blockers? Am J Cardiol. 1996;78:821-822.
18. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
19. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J. 1988;9:8-16.
20. Gurwitz JH, Goldberg RJ, Chen Z, Gore JM, Alpert JS. Beta-blocker therapy in acute myocardial infarction, evidence for underutilization in the elderly. Am J Med. 1992;93:605-610.
21. Lichstein E, Hager WD, Gregory JJ, et al for The Multicenter Diltiazem Post-Infarction Research Group. Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. J Am Coll Cardiol. 1990;16:1327-1332.
22. Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA 1982;247:1707-1714.
23. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
24. Kjekshus J, Gilpin E, Cali G, et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J. 1990;11:43-50.
25. Montague TJ, Ikuta RM, Wong RY, et al. Comparison of risk and patterns of practice in patients older and younger than 70 years with acute myocardial infarction in a two-year period (1987-1989). Am J Cardiol. 1991;68:843-847.
26. Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of B-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in hemodynamic, contractile and diastolic performance with bucindolol. Circulation. 1990;82:473-483.
27. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effects of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: a randomized double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310-1320.
28. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678-1687.
29. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol therapy improves LV function and symptoms in heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225-1231.
30. Quaife, Udelson JE, Bacharach SL, Cannon RO, Bonow RO. Minimum LV pressure during B-adrenergic stimulation in human subjects. Circulation. 1990;82:1174-1182.
31. 1-adrenergic receptor partial agonist xamoterol on LV diastolic function. Circulation. 1990;81:87-98.
32. Quaife R, Gilbert EM, Christian PE, Datz FL. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol. 1996;78:779-784.
33. Eichhorn EJ, Bristow MR. Practical Guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 1997;79:794-798.
34. Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol. 1997;29:1060-1066.
35. Packer M, Bristow MR, Cohn JN, et al. Carvedilol reduced mortality and hospitalization in chronic heart failure. N Engl J Med. 1996;334:1349-1355.
36. CIBIS Investigator and Committees. A randomized trial of β-blockade in heart failure. Circulation. 1994;90:1765-1773.
37. Douban S, Brodsky MA, Whang DD, Whang R. Significance of magnesium in congestive heart failure. Am Heart J. 1996;132:664-671.
38. The Pimobendan in Congestive Heart Failure (PICO) Investigators. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart. 1996;76:223-231.
39. Katz SD, Kubo SH, Jessup M, et al. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J. 1992;123:95-103.
40. Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation. 1995;92:3264-3272.
41. Massie BM, Fisher SG, Deedwania PC, Singh BN, Fletcher RD, Singh SN for the CHF-STAT Investigators. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation. 1996;93:2128-2134.
42. Singh SN, Fleteher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia (Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure). N Engl J Med. 1995;333:77-82.
43. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457-465.
44. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study (RALES]). Am J Cardiol. 1996;78:902-907.
45. Hobbs RE, Miller LW, Bott-Silverman C, et al. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996;78:896-901.
46. Timmermans P, Smight RD. A new class of therapeutic agents: the angiotensin II receptor antagonists. Cardiologia. 1994;39:397-400.
47. Pitt B, Chang P, Grossman W, et al. Rationale, background, and design of the Randomized Angiotensin Receptor Antagonist-Angiotensin-Converting Enzyme Inhibitor Study (RAAS). Am J Cardiol. 1996;78:1129-1131.
48. Kostis JB. Angiotensin II-receptor blockers: profile of a new drug class for antihypertensive therapy. Am J Geriatr Cardiol. 1996;5:11-19.
49. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995;26:438-445.
50. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88:1602-1609.
51. Spinale FG, Gasparo M, Whitebread S, et al. The unique effects of combined angiotensin converting enzyme inhibition and angiotensin II receptor blockade on neurohormonal system activation and myocyte contractile processes with developing congestive heart failure. Circulation. 1996;94(suppl 1):1428-1440.
52. Baruch L, Anand IS, Judd DL, et al. Hemodynamic response to AT1 receptor blockade with valsartan in ACE inhibitor-treated patients with heart failure. Circulation. 1996;94(suppl 1):1428-1440.
53. Cleland JGF. Renal response to candoxatril in patients with heart failure. J Am Coll Cardiol. 1995; 25:1273-1281.
54. Newby DE, McDonagh T, Currie PF, Boon NA, Dargie HG. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition [abstract]. J Am Coll Cardiol. 1997;29:169A.